WASHINGTON, Jan. 30, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2023 Results Net earnings were $1.1 billion, or $1.50 per diluted common share and non-GAAP adjusted diluted... Read more
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model... Read more
WASHINGTON, Dec. 21, 2023 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The... Read more
WASHINGTON, Dec. 6, 2023 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher”) announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) (“Abcam”). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the “Scheme”) and the Scheme became effective... Read more
WASHINGTON, Oct. 31, 2023 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Biotechnology business, effective January 1, 2024. Mr. Riley, currently Vice President and... Read more
WASHINGTON, Oct. 24, 2023 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the third quarter ended September 29, 2023. Net earnings refer to net earnings attributable to common shareholders. Results for the third quarter include the operations of Veralto Corporation, which was spun-off to Danaher’s shareholders on September 30, 2023. Key... Read more
WASHINGTON, Sept. 30, 2023 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off of Veralto Corporation. Veralto will begin “regular way” trading on the New York Stock Exchange on October 2, 2023, under the symbol “VLTO.” “Today marks an exciting milestone... Read more
WASHINGTON, Sept. 26, 2023 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour. During the call, the company will discuss its financial performance, as well as future expectations. The... Read more
New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the Global Fund to provide Cepheid’s Xpert® MTB/RIF Ultra diagnostic test cartridges for TB at cost, with no profit to Danaher. WASHINGTON, Sept. 19, 2023 /PRNewswire/... Read more
WASHINGTON, Aug. 31, 2023 /PRNewswire/ — Danaher Corporation (NYSE: DHR) will host a live video webcast of Veralto’s Investor and Analyst Meeting on September 6, 2023 beginning at approximately 12:00 p.m. CT. The event, which will provide a comprehensive overview of Veralto and its operating segments, will be held at Videojet’s facility in Wood Dale,... Read more